The stock's rise snapped a four-day losing streak.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) last posted its earnings results on Monday, February 10th.